People

  1. Sklarin
    Sklarin
  2. Gilheeney
    Gilheeney
  3. McGill
    McGill
  4. Zhang
    Zhang
  5. Siegel
    Siegel
  6. Velardi
    Velardi
  7. Nguyen
    Nguyen
  8. Gibson
    Gibson
  9. Davis
    Davis
  10. Sevak
    Sevak
  11. Deng
    Deng
  12. Bouvier
    Bouvier
  13. Wickersham
    Wickersham
  14. Aragones
    Aragones
  15. Hennessey
    Hennessey

Recent Works

  1. Patient-centered outcomes in ARIEL3, a phase 3, randomized, placebo-controlled study of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma
    Meeting Abstract

    Bedel, D. J.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; Leary, A.; more...
    Value in Health (2019)

    Fulltext@MSK | Save
  2. Cost-effectiveness of a 24-month fixed duration of venetoclax in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia in the United States
    Meeting Abstract

    Huntington, S. F.; Strunz-McKendry, T.; Masaquel, A. S.; Shapouri, S.; Sail, K.; Durno, N.; Mato, A.
    Value in Health (2019)

    Fulltext@MSK | Save
  3. Quality adjusted time without symptoms of disease progression or toxicity (Q-TWIST) of nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) among untreated advanced renal cell carcinoma (ARCC) patients (patients) with intermediate or poor prognostic risk
    Meeting Abstract

    Shah, R.; Botteman, M.; Kwon, Y.; Gooden, K. M.; Cella, D.; Motzer, R.
    Value in Health (2019)

    Fulltext@MSK | Save